z-logo
open-access-imgOpen Access
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Author(s) -
Federico Bertoglio,
Viola Fühner,
Maximilian Ruschig,
Philip Alexander Heine,
Leila Abassi,
Thomas Klünemann,
Ulfert Rand,
Doris Meier,
Nora Langreder,
Stephan Steinke,
Rico Ballmann,
Kai-Thomas Schneider,
Kristian Daniel Ralph Roth,
Philipp Kühn,
Peggy Riese,
Dorina Schäckermann,
Janin Korn,
Allan Koch,
M. Zeeshan Chaudhry,
Kathrin Eschke,
Yeonsu Kim,
Susanne ZockEmmenthal,
Marlies Becker,
M Scholz,
Gustavo Marçal Schmidt Garcia Moreira,
Esther Veronika Wenzel,
Giulio Russo,
Hendrikus S.P. Garritsen,
Sebastian Casu,
Andreas O. H. Gerstner,
Günter Roth,
Julia M. Adler,
Jakob Trimpert,
Andreas Hermann,
Thomas Schirrmann,
Stefan Dübel,
André Frenzel,
Joop van den Heuvel,
Luka ČičinŠain,
Maren Schubert,
Michael Hust
Publication year - 2021
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2021.109433
Subject(s) - covid-19 , virology , neutralizing antibody , antibody , sars virus , biology , medicine , virus , genetics , outbreak , infectious disease (medical specialty) , disease , pathology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom